Related Experiment Video
Updated: Jul 12, 2026

Galleria mellonella as an Antimicrobial Screening Model
Published on: October 11, 2024
Back to the future: using aminoglycosides again and how to dose them optimally
George L Drusano1, Paul G Ambrose, Sujata M Bhavnani
1Ordway Research Institute, Albany, NY 12208, USA. gdrusano@ordwayresearch.org
Abstract:
Gram-negative organisms have become increasingly resistant to both beta-lactam antibiotics and fluoroquinolones. Consequently, aminoglycoside antibiotics have undergone a resurgence in use. Because of the known toxicities of aminoglycoside antibiotics, clinicians have avoided their use, unless no other alternatives were extant. Over the past 2 decades, we have learned much about the relationship between aminoglycoside exposure and the likelihood of a good clinical outcome or the occurrence of nephrotoxicity. For example, minimum inhibitory concentration values > or = 2.0 mg/L lead to unacceptably low probabilities of a good clinical outcome, and infrequent administration of doses (i.e., intervals of 24 h and longer intervals for patients with compromised renal function) plays a central role in minimizing the likelihood of toxicity. Using these new insights, we suggest ways of evaluating the dose and schedule of administration of aminoglycosides in empirical therapy to obtain the highest likelihood of an efficacious and nontoxic therapy.
Insights
Aminoglycoside antibiotics are increasingly used due to resistance to other drugs. Optimal dosing and infrequent administration minimize toxicity and maximize efficacy for Gram-negative infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Pharmacy
Background:
- Growing resistance of Gram-negative bacteria to beta-lactam antibiotics and fluoroquinolones necessitates alternative treatments.
- Aminoglycoside antibiotics are experiencing a resurgence in clinical use due to their efficacy against resistant Gram-negative pathogens.
- Historical avoidance of aminoglycosides due to toxicity concerns is being re-evaluated with new data.
Purpose of the Study:
- To review the relationship between aminoglycoside exposure and clinical outcomes, including efficacy and nephrotoxicity.
- To provide evidence-based recommendations for optimizing aminoglycoside dosing and administration schedules.
- To guide empirical therapy with aminoglycosides for improved efficacy and reduced toxicity.
Main Methods:
- Analysis of existing literature and clinical data on aminoglycoside pharmacokinetics and pharmacodynamics.
- Evaluation of minimum inhibitory concentration (MIC) values in relation to treatment success.
- Assessment of dosing frequency and its impact on nephrotoxicity and clinical outcomes.
Main Results:
- Minimum inhibitory concentration (MIC) values of 2.0 mg/L or higher are associated with poor clinical outcomes.
- Infrequent administration, specifically 24-hour or longer intervals, is crucial for minimizing aminoglycoside-induced nephrotoxicity.
- Understanding the exposure-toxicity-efficacy relationship allows for safer aminoglycoside use.
Conclusions:
- Optimizing aminoglycoside dosing and scheduling is essential for effective treatment of Gram-negative infections.
- Therapeutic drug monitoring and individualized dosing strategies can enhance efficacy and reduce adverse events.
- Evidence-based guidelines for aminoglycoside use can improve patient outcomes in the era of increasing antibiotic resistance.
Related Concept Videos
Estimation of k and VD of Aminoglycosides
Inhibitors of Bacterial Protein Synthesis
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Geriatric Patients
